Zymeworks Inc (ZYME)
NYSE:ZYME
Zymeworks Stock Analysis & Ratings
ZYME Stock Chart & Stats
Day’s Range$5.17 - $5.845
52-Week Range$4.56 - $39.41
Previous Close$5.88
Volume865.69K
Average Volume (3M)1.56M
Market Cap$296.94M
P/E Ratio-1.3
Beta1.05
Next EarningsAug 03, 2022
EPS Forecast-$0.97
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$21.14
Smart Score7
EPS (TTM)-4.51
Zymeworks News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $4.56 and its highest was $39.41 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $296.94M.
What is Zymeworks’s price target?
The average price target for Zymeworks is $21.14. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $7.00. The average price target represents 311.28% Increase from the current price of $5.14.
The highest analyst price target is $45.00 ,the lowest forecast is $7.00. The average price target represents 311.28% Increase from the current price of $5.14.
What do analysts say about Zymeworks?
Zymeworks’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on May 04, 2022. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$0.981 by -$0.209.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zymeworks have?
Zymeworks has 39,310,000 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$1.19 in its last earnings report, missing expectations of -$0.981. Following the earnings report the stock price went down -7.681%.
Which hedge fund is a major shareholder of Zymeworks?
Among the largest hedge funds holding Zymeworks’s share is Perceptive Advisors LLC. It holds Zymeworks’s shares valued at 35M.
---
Zymeworks Stock Analysis
Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Price Target
$21.14
Strong Buy▲(311.28% Upside)
Analyst Forecast
Strong Buy
Average Price Target: $21.14
Blogger Sentiment
Bullish
ZYME Sentiment 100% Sector Average 71%
Hedge Fund Holdings
▲ Increased
By 1.7M Shares Last Quarter.
Insider Transactions
▼ Sold Shares
Worth $20.5K over the Last 3 Months
Retail Investors
Very Positive
Last 7 Days ▲ 2.0% Last 30 Days ▲ 13.5%
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.22%
12-Months-Change
Fundamentals
Return on Equity
-72.74%
Trailing 12-Months
Asset Growth
-12.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
Company
Price & Change
Follow
Merck & Company
―
Sorrento Therapeutics
―
Eloxx Pharmaceuticals
―
Eli Lilly & Co
―
Sesen Bio
―
---